High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer
High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer
复制标题
DOI：
10.1016/s0022-5347(05)65855-7
复制
发表时间：
2001-09-01
影响因子：
6.6
通讯作者：
Leibel, SA
中科院分区：
文献类型：
--
作者：
Zelefsky, MJ;Fuks, Z;Leibel, SA
目的：我们提出了长期的结果和耐受性的三维（D）适形和调强放射治疗局部prostate cancer.Materials和方法：1988年10月至1998年12月，1,100例临床分期T1 c-T3前列腺癌进行了治疗与3-D适形或调强放射治疗。根据治疗前前列腺特异性抗原（PSA）、Gleason评分和临床分期将患者分为预后风险组。在治疗后2.5年或更长时间进行六等分活检，以评估局部控制。根据美国放射治疗肿瘤学会的共识指南定义PSA复发。根据放射治疗肿瘤组发病率分级量表对晚期毒性进行分类。结果：5年时，PSA无复发生存率在有利、中等和不利风险的患者中分别为85%（95%可信区间[CI] +/-4）、58%（95% CI +/-6）和38%（95% CI +/-6）（p
Purpose: We present the long-term outcome and tolerance of 3-dimensional (D) conformal and intensity modulated radiation therapy for localized prostate cancer.Materials and Methods: Between October 1988 and December 1998, 1,100 patients with clinical stages T1c-T3 prostate cancer were treated with 3-D conformal or intensity modulated radiation therapy. Patients were categorized into prognostic risk groups based on pretreatment prostate specific antigen (PSA), Gleason score and clinical stage. Sextant biopsies were performed 2.5 years or greater after treatment to assess local control. PSA relapse was defined according to the consensus guidelines of the American Society for Therapeutic Radiation Oncology. Late toxicity was classified according to the Radiation Therapy Oncology Group morbidity grading scale. Median followup was 60 months.Results: At 5 years the PSA relapse-free survival rate in patients at favorable, intermediate and unfavorable risk was 85% (95% confidence interval [CI] +/- 4), 58% (95% CI +/- 6) and 38% (95% CI +/- 6), respectively (p